| Editor's Note: Happy solar eclipse day! |
Today’s Big NewsApr 8, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Annalee Armstrong The sun is shining in San Diego, but you wouldn’t really know it from the cavernous exhibit hall of the American Association for Cancer Research annual meeting. Instead, you’re met by the sounds of an espresso machine, the smell of roasted coffee beans, a hum of chatter and—what was that? A dog barking? |
|
|
|
By Angus Liu Merely hours after Bristol Myers Squibb’s Abecma secured the FDA’s blessing to break into earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti received a similar go-ahead—but in an even earlier setting and with expanded manufacturing specifications. |
By Conor Hale It's Impella's first positive result from a randomized trial showing increases in 6-month survival after acute myocardial infarction and cardiogenic shock. |
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
|
Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now. 
|
|
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Angus Liu At the inaugural AACR Oncology Industry Partnering Event, the FDA's oncology chief Richard Pazdur, M.D., addressed some key topics at his department, including accelerated approval and confirmatory trial requirement, advisory committee meeting, some new regulatory initiatives and even his succession plan. |
By Fraiser Kansteiner With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s reach in the United States. |
By Nick Paul Taylor Madrigal Pharmaceuticals already has physicians singing from its hymn sheet. Shortly after the biotech won approval in metabolic dysfunction-associated steatohepatitis, most gastroenterologists said they were familiar with its drug and planning to trial the brand within six months of its launch. |
By Conor Hale The agency’s de novo clearance for the ImmunoScore software allows it to help predict cases where the body’s immune system may severely overreact to an infection. |
By Annalee Armstrong Regeneron’s multiple myeloma medicine, which was accepted for priority review at the FDA in February, is showing durability in the latest data drop from a phase 1/2 test. |
By Kevin Dunleavy In a year in which Vertex Pharmaceuticals saw its share price swell by 41%, the Boston company rewarded its CEO in kind. In her third full year as the CEO, Reshma Kewalramani, M.D., collected $20.6 million in total compensation in 2023, an increase of 30% from $15.9 million in 2022. |
By Andrea Park Though men are more likely to develop aortic stenosis, studies have shown that when it comes to severe cases, women—who are often older and more symptomatic than their male counterparts when they’re diagnosed—have a higher mortality rate, even after controlling for the age differences. |
By Conor Hale Caption’s AI offers step-by-step guidance to help relatively inexperienced technicians capture diagnostic images of a beating heart in real time—typically a difficult process, which has previously required specialized training. |
By Gabrielle Masson Ionis previously touted that olezarsen was 100% effective in a rare metabolic disorder after a phase 3 readout. Now, the full data set is slightly denting that statistic while leaving plenty of room for a planned regulatory filing later this year. |
By Zoey Becker The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The following year, the agency doled out a complete response letter, dashing Supernus' second try. |
By Andrea Park Almost 40% of doctors surveyed said they’d stick with brand-name drugs if generics’ cost savings were taken out of the equation. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
